Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6) |
| |
Authors: | Wagner Uwe,du Bois Andreas,Pfisterer Jacobus,Huober Jens,Loibl Sybille,Lück Hans-Joachim,Sehouli Jalid,Gropp Martina,Stähle Anne,Schmalfeldt Barbara,Meier Werner,Jackisch Christian AGO Ovarian Cancer Study Group |
| |
Affiliation: | Department of Gynecology, Gynecologic Endocrinology and Oncology, Philipps-University Marburg, Baldingerstrasse, D-35043 Marburg, Germany. uwe.wagner@med.uni-marburg.de |
| |
Abstract: | BACKGROUND: Tamoxifen and gefitinib (IRESSA) combination therapy was studied in patients with ovarian cancer refractory or resistant to platinum- and taxane-based therapy. PATIENTS AND METHODS: In this phase II study, 56 patients with epithelial ovarian carcinoma or cancer of the fallopian tube or peritoneum received oral tamoxifen 40 mg/day and gefitinib 500 mg/day until progression or unacceptable toxicity. RESULTS: Seventeen patients (mean age: 59.6 years) had previously received first-line platinum/taxane treatment only, while 39 had received 2-8 (median 2) prior chemotherapy regimens. Gefitinib dose reduction to 250 mg/day was performed in 10 patients (14.9%), predominantly due to diarrhea (6 patients [10.7%]). Trial medication was discontinued in 6 patients (10.7%) due to adverse events (AEs). The most frequent drug-related AEs were diarrhea and acne-like skin rash. There were no tumor responses, but 16 patients had stable disease. Median time-to-progression was 58 days (95% CI, 55-71 days) and median survival was 253 days (95% CI, 137-355 days). CONCLUSION: Gefitinib plus tamoxifen did not appear to be efficacious in the treatment of patients with refractory/resistant ovarian cancer. The addition of tamoxifen did not worsen the known side effects of gefitinib, or induce additional side effects. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|